Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2012

01-12-2012

Fructose-1,6-Bisphosphate and N-Acetylcysteine Attenuate the Formation of Advanced Oxidation Protein Products, a New Class of Inflammatory Mediators, In Vitro

Authors: Guilherme Vargas Bochi, Vanessa Dorneles Torbitz, Lara Peruzzolo Cargnin, Manuela Borges Sangoi, Roberto Christ Vianna Santos, Patrícia Gomes, Rafael Noal Moresco

Published in: Inflammation | Issue 6/2012

Login to get access

Abstract

The accumulation of advanced oxidation protein products (AOPP) has been linked to several pathological conditions. Previous studies have identified AOPP as a novel biomarker of oxidative damage to proteins and a novel class of mediator of inflammation. The aim of this study was to determine the effects of fructose-1,6-bisphosphate (FBP) and N-acetylcysteine (NAC) as well as the synergistic effect of both treatments on the formation of AOPP in vitro. For this purpose, we incubated the human serum albumin (HSA) with various hypochlorous acid (HOCl) concentrations to produce albumin-advanced oxidation protein products (HSA-AOPP). Both FBP and NAC were capable of inhibiting the formation of HOCl-induced AOPP in a concentration-dependent manner. The synergistic effect promoted by the association of these drugs showed to be more effective than when tested alone. Thus, both FBP and NAC may be good candidates to mitigate and neutralize pro-inflammatory and pro-oxidant effects of AOPP in several diseases.
Literature
1.
Hancock, J.T., R. Desikan, and S.J. Neill. 2001. Role of reactive oxygen species in cell signalling pathway. Biochemical Society Transactions 29: 345–350.PubMedCrossRef
2.
Asaba, K., A. Tojo, M.L. Onozato, A. Goto, M.T. Quinn, T. Fujita, and C.S. Wilcox. 2005. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney International 67: 1890–1898.PubMedCrossRef
3.
Halliwell, B. 1992. Reactive oxygen species and the central nervous system. Journal of Neurochemistry 59: 1609–1623.PubMedCrossRef
4.
Dalle-Donne, I., R. Rossi, R. Colombo, D. Giustarini, and A. Milzani. 2006. Biomarkers of oxidative damage in human disease. Clinical Chemistry 52: 601–623.PubMedCrossRef
5.
Miyata, T., and C.Y. de Strihou. 2010. Diabetic nephropathy: a disorder of oxygen metabolism? Nature Reviews Nephrology 6: 83–95.PubMedCrossRef
6.
7.
Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304–1313.PubMedCrossRef
8.
Shi, X.Y., F.F. Hou, H.X. Niu, G.B. Wang, D. Xie, Z.J. Guo, Z.M. Zhou, F. Yang, J.W. Tian, and X. Zhang. 2008. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149: 1829–1839.PubMedCrossRef
9.
Zhou, L.L., F.F. Hou, G.B. Wang, F. Yang, D. Xie, Y.P. Wang, and J.W. Tian. 2009. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney International 76: 1148–1160.PubMedCrossRef
10.
Hanasand, M., R. Omdal, K.B. Norheim, L.G. Gøransson, C. Brede, and G. Jonsson. 2012. Improved detection of advanced oxidation protein products in plasma. Clinica Chimica Acta 413: 901–906.CrossRef
11.
Kalousová, M., J. Skrha, and T. Zima. 2002. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiological Research 51: 597–604.PubMed
12.
Martín-Gallán, P., A. Carrascosa, M. Gussinyé, and C. Domínguez. 2003. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radical Biology & Medicine 34: 1563–1574.CrossRef
13.
Tabak, O., R. Gelisgen, H. Erman, F. Erdenen, C. Muderrisoglu, H. Aral, and H. Uzun. 2011. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clinical and Investigative Medicine 34: 163–171.
14.
Chen, S., L. Liu, X. Sun, Y. Liu, and T. Son. 2005. Captopril restores endothelium-dependent relaxation induced by advanced oxidation protein products in rat aorta. Journal of Cardiovascular Pharmacology 46: 803–809.PubMedCrossRef
15.
Atabek, M.E., M. Keskin, C. Yazici, M. Kendirci, N. Hatipoglu, E. Koklu, and S. Kurtoglu. 2006. Protein oxidation in obesity and insulin resistance. European Journal of Pediatrics 165: 753–756.PubMedCrossRef
16.
Gröne, H.J., E.F. Gröne, and E. Malle. 2002. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Laboratory Investigation 82: 5–14.PubMedCrossRef
17.
Kaneda, H., J. Taguchi, K. Ogasawara, T. Aizawa, and M. Ohno. 2002. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162: 221–225.PubMedCrossRef
18.
Witko-Sarsat, V., T. Nguyen Khoa, P. Jungers, T. Drüeke, and B. Descamps-Latscha. 1998. Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Advances in Nephrology from the Necker Hospital 28: 321–341.PubMed
19.
Capeillère-Blandin, C., V. Gausson, B. Descamps-Latscha, and V. Witko-Sarsat. 2004. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochimica et Biophysica Acta 1689: 91–102.PubMedCrossRef
20.
Descamps-Latscha, B., and V. Witko-Sarsat. 2001. Importance of oxidatively modified proteins in chronic renal failure. Kidney International. Supplement 78: 108–113.CrossRef
21.
Witko-Sarsat, V., V. Gausson, A.T. Nguyen, M. Touam, T. Drüeke, F. Santangelo, and B. Descamps-Latscha. 2003. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney International 64: 82–91.PubMedCrossRef
22.
Fahlman, C.S., P.E. Bickler, B. Sullivan, and G.A. Gregory. 2002. Activation of the neuroprotective ERK signaling pathway by fructose-1,6-bisphosphate during hypoxia involves intracellular Ca2+ and phospholipase C. Brain Research 958: 43–51.PubMedCrossRef
23.
De Oliveira, J.R., J.L. Rosa, S. Ambrosio, and R. Bartrons. 1992. Effect of galactosamine on hepatic carbohydrate metabolism: protective role of fructose 1,6-bisphosphate. Hepatology 15: 1147–1153.PubMedCrossRef
24.
Nunes, F.B., C.M. Graziottin, J.C. Alves Filho, A. Lunardelli, M.G. Pires, P.H. Wächter, and J.R. De Oliveira. 2003. An assessment of fructose-1,6-bisphosphate as an antimicrobial and anti-inflammatory agent in sepsis. Pharmacological Research 47: 35–41.PubMedCrossRef
25.
Cotgreave, I.A. 1997. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Advances in Pharmacology 38: 205–227.PubMedCrossRef
26.
Nascimento, M.M., M.E. Suliman, M. Silva, T. Chinaglia, J. Marchioro, S.Y. Hayashi, M.C. Riella, B. Lindholm, and B. Anderstam. 2010. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Peritoneal Dialysis International 30: 336–342.PubMedCrossRef
27.
Morris, J.C. 1966. The acid ionization constant of HOCl from 5 to 35. The Journal of Physical Chemistry 70: 3798–3805.CrossRef
28.
Iwao, Y., M. Anraku, M. Hiraike, K. Kawai, K. Nakajou, T. Kai, A. Suenaga, and M. Otagiri. 2006. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metabolism and Pharmacokinetics 21: 140–146.PubMedCrossRef
29.
Hawkins, C.L., D.I. Pattison, and M.J. Davies. 2003. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids 25: 259–274.PubMedCrossRef
30.
Hazell, L.J., J.J. van den Berg, and R. Stocker. 1994. Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. The Biochemical Journal 302: 297–304.PubMed
31.
Kettle, A.J. 1996. Neutrophils convert tyrosyl residues in albumin to chlorotyrosine. FEBS Letters 379: 103–106.PubMedCrossRef
32.
Yang, C.Y., Z.W. Gu, H.X. Yang, M. Yang, A.M. Gotto, and C.V. Smith. 1997. Oxidative modifications of apoB-100 by exposure of low density lipoproteins to HOCL in vitro. Free Radical Biology & Medicine 23: 82–89.CrossRef
33.
Thomas, E.L., M.B. Grisham, and M.M. Jefferson. 1986. Preparation and characterization of chloramines. Methods in Enzymology 132: 569–585.PubMedCrossRef
34.
Mera, K., R. Nagai, N. Haraguchi, Y. Fujiwara, T. Araki, N. Sakata, and M. Otagiri. 2007. Hypochlorous acid generates N epsilon-(carboxymethyl)lysine from Amadori products. Free Radical Research 41: 713–718.PubMedCrossRef
35.
Fu, S., H. Wang, M. Davies, and R. Dean. 2000. Reactions of hypochlorous acid with tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products in addition to 3-chlorotyrosine. The Journal of Biological Chemistry 75: 10851–10858.CrossRef
36.
Himmelfarb, J., E. McMonagle, and E. McMenamin. 2000. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney International 58: 2571–2578.PubMedCrossRef
37.
Mera, K., M. Anraku, K. Kitamura, K. Nakajou, T. Maruyama, and M. Otagiri. 2005. The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochemical and Biophysical Research Communications 334: 1322–1328.PubMedCrossRef
38.
Peskin, A.V., and C.C. Winterbourn. 2001. Kinetics of the reactions of hypochlorous acid and amino acid chloramines with thiols, methionine and ascorbate. Free Radical Biology & Medicine 30: 572–579.CrossRef
39.
Alva, N., T. Carbonell, T. Roig, J. Bermúdez, and J. Palomeque. 2011. Fructose 1,6 biphosphate administration to rats prevents metabolic acidosis and oxidative stress induced by deep hypothermia and rewarming. European Journal of Pharmacology 659: 259–264.PubMedCrossRef
40.
Bajić, A., J. Zakrzewska, D. Godjevac, P. Andjus, D.R. Jones, M. Spasić, and I. Spasojević. 2011. Relevance of the ability of fructose 1,6-bis(phosphate) to sequester ferrous but not ferric ions. Carbohydrate Research 346: 416–420.PubMedCrossRef
41.
McGilvery, R.W. 1953. Cyclohexylammonium fructose-1, 6-diphosphates. The Journal of Biological Chemistry 200: 835–838.PubMed
42.
Song, Y., and M.R. Gunner. 2009. Using multiconformation continuum electrostatics to compare chloride binding motifs in alpha-amylase, human serum albumin and Omp32. Journal of Molecular Biology 387: 840–856.PubMedCrossRef
43.
Santos, R.C., R.N. Moresco, M.A. Peña Rico, A.R. Susperregui, J.L. Rosa, R. Bartrons, F. Ventura, D.N. Mário, S.H. Alves, E. Tatsch, H. Kober, R.O. de Mello, P. Scherer, H.B. Dias, and J.R. de Oliveira. 2012. Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease. Inflammation. doi:10.​1007/​s10753-012-9436-7.
44.
de Mello, R.O., A. Lunardelli, E. Caberlon, C.M. de Moraes, R. Christ Vianna Santos, V.L. da Costa, G.V. da Silva, P. da Silva Scherer, L.E. Buaes, D.A. da Silva Melo, M.V. Donadio, F.B. Nunes, and J.R. de Oliveira. 2011. Effect of N-acetylcysteine and fructose-1,6-bisphosphate in the treatment of experimental sepsis. Inflammation 34: 539–50.PubMedCrossRef
45.
Lian, X.Y., F.A. Khan, and J.L. Stringer. 2007. Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. The Journal of Neuroscience 27: 12007–12011.PubMedCrossRef
46.
Moresco, R.N., R.C. Santos, J.C. Alves Filho, A.A. Cunha, C. Dos Reis, C.L. Reichel, and J.R. De Oliveira. 2004. Protective effect of fructose-1,6-bisphosphate in the cold storage solution for liver preservation in rat hepatic transplantation. Transplantation Proceedings 36: 1261–1264.PubMedCrossRef
47.
Xu, M., D.Z. Dai, Q. Zhang, Y.S. Cheng, and Y. Dai. 2010. Upregulated NADPH oxidase contributes to diabetic testicular complication and is relieved by strontium fructose 1,6-diphosphate. Experimental and Clinical Endocrinology & Diabetes 118: 459–465.CrossRef
48.
Gámez, A., N. Alva, T. Roig, J. Bermúdez, and T. Carbonell. 2008. Beneficial effects of fructose 1,6-biphosphate on hypothermia-induced reactive oxygen species injury in rats. European Journal of Pharmacology 590: 115–119.PubMedCrossRef
49.
Ahn, S.M., J.S. Hwang, and S.H. Lee. 2007. Fructose 1,6-diphosphate alleviates UV-induced oxidative skin damage in hairless mice. Biological and Pharmaceutical Bulletin 30: 692–697.PubMedCrossRef
50.
Calafell, R., J. Boada, A.F. Santidrian, J. Gil, T. Roig, J.C. Perales, and J. Bermudez. 2009. Fructose 1,6-bisphosphate reduced TNF-alpha-induced apoptosis in galactosamine sensitized rat hepatocytes through activation of nitric oxide and cGMP production. European Journal of Pharmacology 610: 128–133.PubMedCrossRef
51.
Rogido, M., I. Husson, C. Bonnier, M.C. Lallemand, C. Mérienne, G.A. Gregory, A. Sola, and P. Gressens. 2003. Fructose-1,6-biphosphate prevents excitotoxic neuronal cell death in the neonatal mouse brain. Brain Research 140: 287–297.PubMedCrossRef
52.
Lazzarino, G., B. Tavazzi, D. Di Pierro, and B. Giardina. 1992. Ischemia and reperfusion: effect of fructose-1,6-bisphosphate. Free Radical Research Communications 16: 325–339.PubMedCrossRef
53.
Akimitsu, T., J.A. White, D.L. Carden, D.C. Gute, and R.J. Korthuis. 1995. Fructose-1,6-diphosphate or adenosine attenuate leukocyte adherence in postischemic skeletal muscle. The American Journal of Physiology 269: 1743–1751.
54.
Ahn, S.M., H.Y. Yoon, B.G. Lee, K.C. Park, J.H. Chung, C.H. Moon, and S.H. Lee. 2002. Fructose-1,6-diphosphate attenuates prostaglandin E2 production and cyclo-oxygenase-2 expression in UVB-irradiated HaCaT keratinocytes. British Journal of Pharmacology 137: 497–503.PubMedCrossRef
55.
Lopes, R.P., A. Lunardelli, T. Preissler, C.E. Leite, J.C. Alves-Filho, F.B. Nunes, J.R. de Oliveira, and M.E. Bauer. 2006. The effects of fructose-1,6-bisphosphate and dexamethasone on acute inflammation and T-cell proliferation. Inflammation Research 55: 354–358.PubMedCrossRef
56.
Aruoma, O.I., B. Halliwell, B.M. Hoey, and J. Butler. 1989. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radical Biology & Medicine 6: 593–597.CrossRef
57.
Fishbane, S. 2008. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clinical Journal of the American Society of Nephrology 3: 281–287.PubMedCrossRef
58.
Holt, S., R. Marley, B. Fernando, D. Harry, R. Anand, D. Goodier, and K. Moore. 1999. Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney International 55: 271–277.PubMedCrossRef
Metadata
Title
Fructose-1,6-Bisphosphate and N-Acetylcysteine Attenuate the Formation of Advanced Oxidation Protein Products, a New Class of Inflammatory Mediators, In Vitro
Authors
Guilherme Vargas Bochi
Vanessa Dorneles Torbitz
Lara Peruzzolo Cargnin
Manuela Borges Sangoi
Roberto Christ Vianna Santos
Patrícia Gomes
Rafael Noal Moresco
Publication date
01-12-2012
Publisher
Springer US
Published in
Inflammation / Issue 6/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9498-6

Other articles of this Issue 6/2012

Inflammation 6/2012 Go to the issue

OriginalPaper

Regulation of Particulate Matter-Induced Mucin Secretion by Transient Receptor Potential Vanilloid 1 Receptors

OriginalPaper

Protective Effect of Magnolol on Lipopolysaccharide-Induced Acute Lung Injury in Mice

OriginalPaper

A Single Nucleotide Polymorphism of IL-21 Gene is Associated with Systemic Lupus Erythematosus in a Chinese Population

OriginalPaper

Cytokine Profile in Patients Undergoing Minimally Invasive Surgery with Balanced Anesthesia

OriginalPaper

The Anti-inflammatory Effect of Z-Ligustilide in Experimental Ovariectomized Osteopenic Rats

OriginalPaper

Polarization Toward Th1-Type Response in Active, but Not in Inactive, Lupus Inhibits Late Allergic Rhinitis in Lupus-Prone Female NZB×NZWF1 Mice
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits